



●▶ **Eisai + Biogen**

(FDA , Approval)

Eisai and Biogen announce that the FDA has approved sBLA for LEQEMBI (lecanemab-irmb) intravenous maintenance dosing for early Alzheimer's disease treatment

●▶ **Johnson & Johnson**

(FDA , Approval)

JNJ's SPRAVATO (esketamine) is the first and only approved monotherapy in the U.S. for adults with treatment-resistant depression

●▶ **Clarity Pharmaceuticals**

(FDA , FTD)

The FDA has issued Fast Track Designation to Clarity's Cu-64 SAR-bisPSMA for PET imaging for PSMA-positive prostate cancer lesions

●▶ **X4 Pharmaceuticals + Norgine**

(EMA , MAA)

X4 Pharmaceuticals Announces EMA Validation of MAA for Mavorixafor for the Treatment of WHIM Syndrome & it is licenced to Norgine for commercialisation in Europe

●▶ **Kelun-Biotech**

(NMPA , Approval)

NMPA approved second indication of Kelun-Biotech's tagitanlimab in combination with cisplatin and gemcitabine for first-line treatment of recurrent or metastatic NPC



●► Glenmark Pharmaceuticals*(Launch)*

Glenmark Pharmaceuticals has launched anticogulant Phytonadione Injectable Emulsion USP, 10 mg/mL in single-dose ampules

●► Stuart Therapeutics*(Clinical Trials)*

Stuart Therapeutics completed its Ph 3 clinical trial of dry eye disease

●► Abbvie*(Collaboration)*

AbbVie + Neomorph have collaborated to develop molecular glue degraders for different targets across oncology and immunology

●► Abbvie*(Acquisition)*

AbbVie has completed the acquisition of Nimble Therapeutics by adding potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to its pipeline and R&D capabilities

●► Fermion & Simcere*(Collaboration)*

Fermion and Simcere have collaborated to develop FZ002-037, a clinical-stage pain treatment asset targeting China's first SSTR4 agonist

